A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease

Launched by THE UNIVERSITY OF HONG KONG · Jul 11, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option called microwave ablation (MWA) for patients with relapsed Graves' disease, a common condition that causes hyperthyroidism. Traditional treatments like anti-thyroid drugs can help some patients, but many experience relapses, and other options like radioactive iodine or surgery can have significant side effects. MWA is a minimally invasive procedure that uses heat generated from microwaves to target and treat the thyroid gland without major surgery. This method is performed under ultrasound guidance, doesn't leave a surgical scar, and allows patients to go home the same day.

To participate in this trial, you need to be at least 18 years old and have experienced a relapse of Graves' disease after at least 18 months of anti-thyroid drug treatment. You also should not have any current issues with your vocal cords. However, if you prefer surgery, have certain neck conditions, or if you are pregnant or breastfeeding, you may not be eligible. Participants can expect a straightforward procedure that aims to provide an effective treatment option with fewer complications compared to traditional methods.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (a) age older than 18 years,
• • (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more
• • (c) absence of vocal cord immobility
• Exclusion Criteria:
• • (a) patients who prefer or are indicated for surgery,
• • (b) presence of head and/or neck disease preventing hyperextension of the neck,
• • (c) history of thyroid cancer or other malignant tumours in the neck region,
• • (d) history of neck irradiation,
• • (e) severe Graves' ophthalmopathy,
• • (f) large compressive goitre,
• • (g) pregnancy or lactation, and
• • (h) any contraindication to intravenous sedation.